Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule.

Front Oncol · 2023 · PMC10264664 · PMID 37324004

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

After a month, a CT scan showed a trend to a reduction of the known lesions and the best overall response (BOR) as partial response (PR) occurred after 14 months of treatment, with subsequent disease progression (PD) after 21 months.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.